LAUSR

Outcomes of vaccination against SARS-COV-2 in organ transplant recipients are unclear. Recent studies have investigated outcomes for patients who are several years post-transplant. There hasn't been much data in peri-transplant patients. This is important because patients are highly immunosuppressed during this period due to induction immunosuppression and thus susceptible to infection. We looked at 6 patients who were transplanted at our center after receiving their first dose of mRNA vaccines. We assessed their antibody response after one, two and in a few cases, three doses of the vaccine. Two patients received their third booster dose, one of whom had a detectable antibody level after the third dose. We report that the overall antibody response to vaccination was weaker in transplant patients compared to the general population with a rapid attrition of antibody response over time. There is a need for more studies which follow-up antibody levels in transplant patients over time, especially those in the peri-transplant period to help guide the vaccination plan and frequency for immunosuppressed transplant patients.